Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
September 14, 2026
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
August 18, 2026
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
August 5, 2026
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
March 23, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
February 12, 2026